GC Corp. (005250.KS)
KSE · KRW · Healthcare · Biotechnology
₩9,210 (+1.32%) as of
Key statistics
- Market cap
- 416.42B
- Dividend yield
- 3.22%
- 52-week range
- 8,630.00 – 18,010.00
- Beta
- 0.56
- Revenue (TTM)
- 2.49T
- Profit margin
- -4.91%
- Volume
- 16.95k
About GC Corp.
GC Corp. operates as a biotechnology company. The company provides prescription drugs and over-the-counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pertussis, tuberculosis, and varicella; recombinant treatments for acquired thrombotic thrombocytopenic purpura, fabry, hemophilia, hunterase, colon cancer, and hunter syndrome; and small molecules for gangliosidosis andalagille's syndrome. The company has partnerships and collaborations with biotech companies and academia for development of new drugs and technologies, and clinical trials. Additionally, the company provides personalized nutrition injections. The company was formerly known as Green Cross Holdings Corporation and changed its name to GC Corp. in April 2026. The company was founded in 1967 and is headquartered in Yongin-Si, South Korea.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Yongin-Si, South Korea
- Employees
- 142
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.